Skip to main content

Table 3 Summary statistics about each dose escalation method

From: Assessment of various continual reassessment method models for dose-escalation phase 1 oncology clinical trials: using real clinical data and simulation studies

A. Clinical trials dose toxicity curves
Dose escalation method MTD selected by dose-escalation method (%)
True selected Underestimated Overestimated < lowest dose
3 + 3   65.2 31.8 2.3 0.7
Extended CRM Step-up 76.7 9.0 13.9 0.4
Dose-Linear 76.7 4.2 21.5 0.4
O’Quigley 76.6 11.6 14.4 0.4
Conservative 74.8 16.6 8.2 0.4
Sigmoidal 73.8 14.7 8.3 0.4
Aggressive 68.5 6.7 24.4 0.4
B. Theoretical dose toxicity curves
Dose escalation method MTD selected by dose-escalation method (%)
True selected Underestimated Overestimated < lowest dose
3 + 3   34.8 42.6 7.3 15.3
Extended CRM Conservative 52.9 21.6 20.7 4.9
Sigmoidal 46.4 19.1 29.9 4.6
Step-up 42.8 22.1 30.1 5.1
O’Quigley 40.6 21.4 32.9 5.1
Aggressive 39.4 21.3 34.5 4.9
Dose-Linear 37.2 18.3 40.4 4.1
C. All dose toxicity curves
Dose escalation method MTD selected by dose-escalation method (%)
True selected Underestimated Overestimated < lowest dose
3 + 3   50.0 37.2 4.8 8.0
Extended CRM Conservative 63.9 19.1 14.4 2.6
Sigmoidal 61.5 16.9 19.1 2.5
Step-up 59.7 15.5 22.0 2.8
O’Quigley 57.1 16.5 23.6 2.7
Dose-Linear 55.5 11.3 31.0 2.2
Aggressive 53.9 14.0 29.4 2.6